Lingual hyperpigmentation with pegylated interferon and ribavirin therapy in patients with chronic hepatitis C.
Sood
Ajit
A
Midha
Vandana
V
Bansal
Manu
M
Goyal
Anuza
A
Sharma
Nidhi
N
D000998:Antiviral Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*; D014060:Tongue Diseases / Q000139:chemically induced*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b